Page last updated: 2024-08-18

2,5-dioxopiperazine and Cardiac Toxicity

2,5-dioxopiperazine has been researched along with Cardiac Toxicity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bures, J; Jansova, H; Jirkovska, A; Karabanovich, G; Kovarikova, P; Roh, J; Sestak, V; Simunek, T; Sterba, M	1

Other Studies

1 other study(ies) available for 2,5-dioxopiperazine and Cardiac Toxicity

Article	Year
Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology, 2017, 12-01, Volume: 392 Topics: Animals; Animals, Newborn; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Daunorubicin; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Iron; Iron Chelating Agents; Myocytes, Cardiac; Rats; Rats, Wistar; Structure-Activity Relationship	2017

Article

Year

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

Toxicology, 2017, 12-01, Volume: 392

Topics: Animals; Animals, Newborn; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Daunorubicin; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Iron; Iron Chelating Agents; Myocytes, Cardiac; Rats; Rats, Wistar; Structure-Activity Relationship

2017